Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR New analysis estimates over 21 million UK adults will be obese... May 18, 2022 Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App September 18, 2021 ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland November 29, 2022 MAP Congress 2020: Molecular Analysis for Precision Oncology October 2, 2020 Load more HOT NEWS Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... How to Make a Homemade Face Mask from a Folded Scarf—No... Nurse With Terminal Breast Cancer Spends Her Days Caring For Pediatric... Newest Gerber Baby is Child of Breast Cancer Survivor
